Milestone Pharmaceuticals is trading at $0.66, down 5.65%, while healthcare shares are under pressure; no direct cause for the intraday decline is confirmed. - Healthcare shares fell 1.29% in the regular session, providing context but not establishing a direct cause. - The latest company release concerned upcoming conference presentations; no verified company announcement on October 23 directly explains the decline. - An October 23 article cited a lower average fair-value estimate and more cautious Cardamyst launch expectations, but did not link them to the move.